Correction
J Med Econ. 2023 Jan-Dec;26(1):1356. doi: 10.1080/13696998.2023.2275924. Epub 2023 Oct 28.NO ABSTRACTPMID:37897715 | DOI:10.1080/13696998.2023.2275924 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 28, 2023 Category: Health Management Source Type: research
The economic impact of obesity in Kuwait: a micro-costing study evaluating the burden of obesity-related comorbidities
CONCLUSIONS: Our study confirms that ORCs generate a significant financial burden to the public payer. The study provides an economic case for policymakers to recognize the exigency for obesity prevention and control in accordance with the ORC prevalence, and the need for sustainable investments towards body-mass index management to prevent individuals from developing multiple comorbidities.PMID:37853705 | DOI:10.1080/13696998.2023.2265721 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: Salman Al-Sabah Amr ElShamy Sharanya Jois Kaywei Low Adrien Gras Ece Parali Gulnar Source Type: research
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China
CONCLUSIONS: The economic burden of lung cancer treatment mainly came from the cost of the drugs. Patients taking chemotherapy had significantly higher cost compared to patients using targeted therapy. The cost was generally higher for those with higher educational level, those with higher family income, and those living in an economically more developed city. Patients with NSCLC had higher cost compared to patients with SCLC.PMID:37855437 | DOI:10.1080/13696998.2023.2272536 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: Kehong Yang Susan Hua Wenting Wei Congyan Yang Xinhai Zhu Shu Chuen Li Source Type: research
The economic impact of obesity in Kuwait: A micro-costing study evaluating the burden of obesity-related comorbidities
ConclusionsOur study confirms that ORCs generate significant financial burden to the public payer. The study provides an economic case for policymakers to recognize the exigency for obesity prevention and control in accordance with the ORC prevalence, and the need for sustainable investments towards body-mass index management to prevent individuals from developing multiple comorbidities.PMID:37853705 | DOI:10.1080/13696998.2023.2265721 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: None Salman Al-Sabah Amr ElShamy Sharanya Jois Kaywei Low Adrien Gras Ece Parali Gulnar Source Type: research
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China
CONCLUSIONS: The economic burden of lung cancer treatment mainly came from the cost of the drugs. Patients taking chemotherapy had significantly higher cost compared to patients using targeted therapy. The cost was generally higher for those with higher educational level, those with higher family income, and those living in an economically more developed city. Patients with NSCLC had higher cost compared to patients with SCLC.PMID:37855437 | DOI:10.1080/13696998.2023.2272536 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: Kehong Yang Susan Hua Wenting Wei Congyan Yang Xinhai Zhu Shu Chuen Li Source Type: research
The economic impact of obesity in Kuwait: A micro-costing study evaluating the burden of obesity-related comorbidities
ConclusionsOur study confirms that ORCs generate significant financial burden to the public payer. The study provides an economic case for policymakers to recognize the exigency for obesity prevention and control in accordance with the ORC prevalence, and the need for sustainable investments towards body-mass index management to prevent individuals from developing multiple comorbidities.PMID:37853705 | DOI:10.1080/13696998.2023.2265721 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: None Salman Al-Sabah Amr ElShamy Sharanya Jois Kaywei Low Adrien Gras Ece Parali Gulnar Source Type: research
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China
CONCLUSIONS: The economic burden of lung cancer treatment mainly came from the cost of the drugs. Patients taking chemotherapy had significantly higher cost compared to patients using targeted therapy. The cost was generally higher for those with higher educational level, those with higher family income, and those living in an economically more developed city. Patients with NSCLC had higher cost compared to patients with SCLC.PMID:37855437 | DOI:10.1080/13696998.2023.2272536 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: Kehong Yang Susan Hua Wenting Wei Congyan Yang Xinhai Zhu Shu Chuen Li Source Type: research
The economic impact of obesity in Kuwait: A micro-costing study evaluating the burden of obesity-related comorbidities
ConclusionsOur study confirms that ORCs generate significant financial burden to the public payer. The study provides an economic case for policymakers to recognize the exigency for obesity prevention and control in accordance with the ORC prevalence, and the need for sustainable investments towards body-mass index management to prevent individuals from developing multiple comorbidities.PMID:37853705 | DOI:10.1080/13696998.2023.2265721 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: None Salman Al-Sabah Amr ElShamy Sharanya Jois Kaywei Low Adrien Gras Ece Parali Gulnar Source Type: research
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China
CONCLUSIONS: The economic burden of lung cancer treatment mainly came from the cost of the drugs. Patients taking chemotherapy had significantly higher cost compared to patients using targeted therapy. The cost was generally higher for those with higher educational level, those with higher family income, and those living in an economically more developed city. Patients with NSCLC had higher cost compared to patients with SCLC.PMID:37855437 | DOI:10.1080/13696998.2023.2272536 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: Kehong Yang Susan Hua Wenting Wei Congyan Yang Xinhai Zhu Shu Chuen Li Source Type: research
The economic impact of obesity in Kuwait: A micro-costing study evaluating the burden of obesity-related comorbidities
ConclusionsOur study confirms that ORCs generate significant financial burden to the public payer. The study provides an economic case for policymakers to recognize the exigency for obesity prevention and control in accordance with the ORC prevalence, and the need for sustainable investments towards body-mass index management to prevent individuals from developing multiple comorbidities.PMID:37853705 | DOI:10.1080/13696998.2023.2265721 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: None Salman Al-Sabah Amr ElShamy Sharanya Jois Kaywei Low Adrien Gras Ece Parali Gulnar Source Type: research
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China
CONCLUSIONS: The economic burden of lung cancer treatment mainly came from the cost of the drugs. Patients taking chemotherapy had significantly higher cost compared to patients using targeted therapy. The cost was generally higher for those with higher educational level, those with higher family income, and those living in an economically more developed city. Patients with NSCLC had higher cost compared to patients with SCLC.PMID:37855437 | DOI:10.1080/13696998.2023.2272536 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: Kehong Yang Susan Hua Wenting Wei Congyan Yang Xinhai Zhu Shu Chuen Li Source Type: research
The economic impact of obesity in Kuwait: A micro-costing study evaluating the burden of obesity-related comorbidities
ConclusionsOur study confirms that ORCs generate significant financial burden to the public payer. The study provides an economic case for policymakers to recognize the exigency for obesity prevention and control in accordance with the ORC prevalence, and the need for sustainable investments towards body-mass index management to prevent individuals from developing multiple comorbidities.PMID:37853705 | DOI:10.1080/13696998.2023.2265721 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: None Salman Al-Sabah Amr ElShamy Sharanya Jois Kaywei Low Adrien Gras Ece Parali Gulnar Source Type: research
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China
CONCLUSIONS: The economic burden of lung cancer treatment mainly came from the cost of the drugs. Patients taking chemotherapy had significantly higher cost compared to patients using targeted therapy. The cost was generally higher for those with higher educational level, those with higher family income, and those living in an economically more developed city. Patients with NSCLC had higher cost compared to patients with SCLC.PMID:37855437 | DOI:10.1080/13696998.2023.2272536 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: Kehong Yang Susan Hua Wenting Wei Congyan Yang Xinhai Zhu Shu Chuen Li Source Type: research
The economic impact of obesity in Kuwait: A micro-costing study evaluating the burden of obesity-related comorbidities
ConclusionsOur study confirms that ORCs generate significant financial burden to the public payer. The study provides an economic case for policymakers to recognize the exigency for obesity prevention and control in accordance with the ORC prevalence, and the need for sustainable investments towards body-mass index management to prevent individuals from developing multiple comorbidities.PMID:37853705 | DOI:10.1080/13696998.2023.2265721 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - October 19, 2023 Category: Health Management Authors: None Salman Al-Sabah Amr ElShamy Sharanya Jois Kaywei Low Adrien Gras Ece Parali Gulnar Source Type: research
